Sage Therapeutics's depression candidate SAGE-217 shows positive treatment effect in Part A of mid-stage study [Seeking Alpha]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Seeking Alpha
Top-line data from Part A (n=13) of a Phase 2 clinical trial assessing Sage Therapeutics' (NASDAQ: SAGE ) SAGE-217 for the treatment of major depressive disorder (MDD) showed it to be well-tolerated with no serious adverse events or discontinuations reported. It also showed encouraging efficacy in reducing MDD symptoms as measured by a scale called HAM-D at Day 15. 85% (n=11/13) of subjects experienced at least a 50% reduction in HAM-D score while 62% (n=8/13) achieved remission (HAM-D score no greater than 7). The trial will now proceed into the placebo-controlled phase. According to ClinicalTrials.gov, the estimated study completion date is December. SAGE-217 , a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function. Now read: Innoviva: Strong Upside As Fears Subside »
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEGlobeNewswire
- Registration for Association of Bioscience Financial Officers 2024 National Conference in May in Boston Nearing Full Capacity [Yahoo! Finance]Yahoo! Finance
- Ex-Stanford President's AI Drug Startup Pulls In $1 Billion in Commitments [BNN Bloomberg (Canada)]BNN Bloomberg
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]Yahoo! Finance
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- SAGE's page on the SEC website